Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
The Netherlands Cancer Institute
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07156253CT.gov Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06797635CT.gov Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | — | Recruiting | — | — | — |
NCT06201234CT.gov Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT06545942CT.gov Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06488378CT.gov Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer | — | Recruiting | — | — | — |
NCT05485766CT.gov Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05900895CT.gov Estradiol Plus Olaparib for Breast Cancer (PHOEBE) | — | Recruiting | — | — | — |
NCT06298084CT.gov Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd | — | Recruiting | — | — | — |
NCT05807126CT.gov Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations | — | Withdrawn | — | — | — |
NCT06065059CT.gov Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | — | Terminated | — | — | — |
Show 59 more trialsShow fewer
NCT06112379CT.gov A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05967286CT.gov Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial | — | Withdrawn | — | — | — |
NCT05332561CT.gov Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | — | Recruiting | — | — | — |
NCT05774886CT.gov Implantable Microdevice for TNBC - Pilot Study | — | Withdrawn | — | — | — |
NCT05564377CT.gov Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | — | Recruiting | — | — | — |
NCT05700669CT.gov Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | — | Completed | — | — | — |
NCT05629429CT.gov Olaparib Maintenance Therapy in Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT05238831CT.gov SMMART Adaptive Clinical Treatment (ACT) Trial | — | Withdrawn | — | — | — |
NCT05536128CT.gov Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor | — | Recruiting | — | — | — |
NCT05498155CT.gov Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05033756CT.gov Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO | — | Active Not Recruiting | — | — | — |
NCT05258747CT.gov A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT05252390CT.gov NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05340413CT.gov Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. | — | Completed | — | — | — |
NCT04711824CT.gov Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases | — | Recruiting | — | — | — |
NCT05203445CT.gov A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04683679CT.gov A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | — | Recruiting | — | — | — |
NCT04856371CT.gov Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer | — | Unknown | — | — | — |
NCT03685331CT.gov HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer | — | Completed | — | — | — |
NCT04586335CT.gov Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | — | Terminated | — | — | — |
NCT04421963CT.gov Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | — | Active Not Recruiting | — | — | — |
NCT04090567CT.gov Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | — | Recruiting | — | — | — |
NCT04330040CT.gov Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04041128CT.gov PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer | — | Completed | — | — | — |
NCT03742245CT.gov Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03931551CT.gov Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer | — | Terminated | — | — | — |
NCT03801369CT.gov AMTEC IIT: Phase 2 Multiarm Study in TNBC | — | Terminated | — | — | — |
NCT03641755CT.gov Olaparib + Sapacitabine in BRCA Mutant Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03568656CT.gov Study to Evaluate CCS1477 in Advanced Tumours | — | Completed | — | — | — |
NCT03544125CT.gov Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03367689CT.gov A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent | — | Terminated | — | — | — |
NCT03344965CT.gov Olaparib In Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03205761CT.gov Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer | — | Completed | — | — | — |
NCT03025035CT.gov Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer | — | Completed | — | — | — |
NCT03162627CT.gov Selumetinib and Olaparib in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03109080CT.gov Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) | — | Completed | — | — | — |
NCT03205176CT.gov AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | — | Completed | — | — | — |
NCT02849496CT.gov Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02810743CT.gov Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03182634CT.gov The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial | — | Unknown | — | — | — |
NCT02789332CT.gov Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency | — | Completed | — | — | — |
NCT02498613CT.gov A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03150576CT.gov Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer | — | Recruiting | — | — | — |
NCT02624973CT.gov PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial | — | Active Not Recruiting | — | — | — |
NCT02681562CT.gov Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients | — | Unknown | — | — | — |
NCT02561832CT.gov A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer | — | Terminated | — | — | — |
NCT02684318CT.gov Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors | — | Unknown | — | — | — |
NCT02418624CT.gov Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer | — | Completed | — | — | — |
NCT02208375CT.gov mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | — | Active Not Recruiting | — | — | — |
NCT02032823CT.gov Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02299999CT.gov SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02000622CT.gov Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. | — | Completed | — | — | — |
NCT01623349CT.gov Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | — | Completed | — | — | — |
NCT01237067CT.gov Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers | — | Completed | — | — | — |
NCT01042379CT.gov I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | — | Recruiting | — | — | — |
NCT00707707CT.gov Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT00679783CT.gov Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer | — | Completed | — | — | — |
NCT01445418CT.gov AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | The Netherlands Cancer Institute | Approved | BB · 66 |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Vitamin D | University of Illinois at Chicago | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Tamoxifen | Dana-Farber Cancer Institute | P4 | BB |
| Adriamycin | George Washington University | P4 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Peg-Rhg-Csf | The First Affiliated Hospital with Nanjing Medical University | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Cancer | — | P4 | BB · 71 |
| Ovarian Carcinoma | — | P4 | BB · 69 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olaparib in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/olaparib-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →